Clinical Trial

A Study to Describe the Safety and Immunogenicity of a Respiratory Syncytial Virus Vaccine IN006 in Healthy Adult Aged 18 Years and Above

Active, Not Recruiting Phase 1
View on ClinicalTrials.gov →
Summary
The study will evaluate the safety, tolerability, and immunogenicity of 3 dose levels of IN006 in healthy adults aged 18 Years and Above; of a revaccination of IN006 given approximately 12 months after the initial vaccination in older adults (aged ≥60 years).
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2024-10-15; most recent amendment 2026-04-01.
Status change: Recruiting → Active, Not Recruiting 2026-04-01
Status change: Not Yet Recruiting → Recruiting 2024-11-18
Trial Details
NCT Number NCT06645665
Lead Sponsor Shenzhen Shenxin Biotechnology Co., Ltd
Conditions Respiratory Syncytial Virus Infections
Enrollment 240 participants
Start Date 2024-11-11
Primary Completion 2027-04 (estimated)
Study Completion 2027-04 (estimated)
Updated on ClinicalTrials.gov 2026-04-02